Key facts
- Mitsui Chemicals will acquire U.S. dental materials manufacturer Ultradent Products for approximately $900 million.
- This acquisition is Mitsui Chemicals' largest to date.
- The deal is expected to close in September 2026, subject to regulatory approvals.
- Ultradent reported consolidated sales of $372.1 million for fiscal year 2025.
- Mitsui plans to relocate its oral care global headquarters to the U.S. post-acquisition.
Mitsui Chemicals announced plans to acquire Ultradent Products, a major U.S.-based dental materials manufacturer, for approximately $900 million. This transaction represents the Japanese chemical producer's largest acquisition to date and is a key move in its strategy to expand its presence in the healthcare sector, particularly in the substantial U.S. market.
The acquisition will be executed through a newly established U.S. Holding Company by Mitsui Chemicals America (MCA). This structure aims to accelerate local decision-making and will also serve as the new global headquarters for Mitsui's oral care business. Ultradent, founded in 1978 and headquartered in South Jordan, Utah, reported consolidated sales of $372.1 million and operating income of $30.9 million for its fiscal year 2025.
Mitsui Chemicals is prioritizing growth in its Life & Healthcare segment, with oral care being a core component of its medical field strategy. The company aims to leverage Ultradent's expertise in design, development, and direct sales of teeth whitening and restorative materials. This is expected to complement the strengths of Kulzer, another Mitsui subsidiary, in the EMEA region and restorative dental solutions. The integration plans involve combining Mitsui's chemical technologies with Ultradent's clinical expertise and Kulzer's prosthetic portfolio to offer a broader range of dental solutions.
The transaction involves MCA acquiring 100% of Ultradent's voting rights from shareholders, including founder Dr. Dan Fischer, for $900 million, with the final price subject to customary adjustments. The board resolution for this decision was made on May 13, 2026, with definitive agreements planned for execution on June 12, 2026. The acquisition is scheduled to be completed in September 2026, contingent upon regulatory approvals and required filings.